Skip Navigation

JNCI Journal of the National Cancer Institute 2004 96(5):351-352; doi:10.1093/jnci/96.5.351
© 2004 by Oxford University Press
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Benowitz, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Benowitz, S.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2004 Oxford University Press

NEWS

As Targeted Therapies Evolve, Challenges Remain

Steven Benowitz

The first 10% of the full text of this article appears below.

When Gleevec burst onto the oncology drug scene several years ago, it did more than revolutionize the treatment of chronic myelogenous leukemia (CML), a rare but deadly cancer. Targeted therapies—and new buzzwords such as "rational design" and "smart drugs"—became all the rage.

Targeted therapies are supposed to be neater and cleaner than the "shotgun" approach of chemotherapy. Such agents attempt to disrupt pathways unique to cancer cells, which they use to grow and communicate, and they theoretically leave normal cells alone and avoid the toxic side effects common with chemotherapy and radiation.

But finding the next Gleevec has turned out to be harder than many scientists thought, and disappointing results early on in the life of some targeted therapies has raised questions about target validation and clinical trial design.

"You have to know the specific drug target and the specific population of patients the . . . [Full Text of this Article]

Understanding Targets

What Went Wrong?

What Can Be Done?


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?